Ranivisio Европейски съюз - словашки - EMA (European Medicines Agency)

ranivisio

midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmologiká - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).

Sigletic 100 mg Словакия - словашки - ŠÚKL (Štátny ústav pre kontrolu liečiv)

sigletic 100 mg

zaklady farmaceutyczne polpharma sa, poľsko - sitagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)

Sigletic 50 mg Словакия - словашки - ŠÚKL (Štátny ústav pre kontrolu liečiv)

sigletic 50 mg

zaklady farmaceutyczne polpharma sa, poľsko - sitagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)

Sigletic 25 mg Словакия - словашки - ŠÚKL (Štátny ústav pre kontrolu liečiv)

sigletic 25 mg

zaklady farmaceutyczne polpharma sa, poľsko - sitagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)